RPRX Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of 41.95% compared to Royalty Pharma PLC's net margin of --. Royalty Pharma PLC's return on equity of 10.92% beat CEL-SCI's return on equity of --.

Royalty Pharma PLC has a consensus price target of $41.90, signalling upside risk potential of 17.73%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 5961.21%. Given that CEL-SCI has higher upside potential than Royalty Pharma PLC, analysts believe CEL-SCI is more attractive than Royalty Pharma PLC.

Royalty Pharma PLC has a beta of 0.503, which suggesting that the stock is 49.658% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.097%.

Royalty Pharma PLC has a quarterly dividend of $0.22 per share corresponding to a yield of 2.42%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 43.83% of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $568.2M, which are larger than CEL-SCI quarterly revenues of --. Royalty Pharma PLC's net income of $238.3M is higher than CEL-SCI's net income of -$6.6M. Notably, Royalty Pharma PLC's price-to-earnings ratio is 15.19x while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 9.26x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

Denali Therapeutics has a net margin of 41.95% compared to Royalty Pharma PLC's net margin of --. Royalty Pharma PLC's return on equity of 10.92% beat Denali Therapeutics's return on equity of --.

Royalty Pharma PLC has a consensus price target of $41.90, signalling upside risk potential of 17.73%. On the other hand Denali Therapeutics has an analysts' consensus of $32.19 which suggests that it could grow by 129.91%. Given that Denali Therapeutics has higher upside potential than Royalty Pharma PLC, analysts believe Denali Therapeutics is more attractive than Royalty Pharma PLC.

Royalty Pharma PLC has a beta of 0.503, which suggesting that the stock is 49.658% less volatile than S&P 500. In comparison Denali Therapeutics has a beta of 1.330, suggesting its more volatile than the S&P 500 by 32.997%.

Royalty Pharma PLC has a quarterly dividend of $0.22 per share corresponding to a yield of 2.42%. Denali Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 43.83% of its earnings as a dividend. Denali Therapeutics pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $568.2M, which are larger than Denali Therapeutics quarterly revenues of --. Royalty Pharma PLC's net income of $238.3M is higher than Denali Therapeutics's net income of -$133M. Notably, Royalty Pharma PLC's price-to-earnings ratio is 15.19x while Denali Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 9.26x versus 6.98x for Denali Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of 41.95% compared to Royalty Pharma PLC's net margin of -711.67%. Royalty Pharma PLC's return on equity of 10.92% beat IGC Pharma's return on equity of -116.24%.

Royalty Pharma PLC has a consensus price target of $41.90, signalling upside risk potential of 17.73%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 979.39%. Given that IGC Pharma has higher upside potential than Royalty Pharma PLC, analysts believe IGC Pharma is more attractive than Royalty Pharma PLC.

Royalty Pharma PLC has a beta of 0.503, which suggesting that the stock is 49.658% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.452, suggesting its more volatile than the S&P 500 by 45.212%.

Royalty Pharma PLC has a quarterly dividend of $0.22 per share corresponding to a yield of 2.42%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 43.83% of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $568.2M, which are larger than IGC Pharma quarterly revenues of $257K. Royalty Pharma PLC's net income of $238.3M is higher than IGC Pharma's net income of -$1.8M. Notably, Royalty Pharma PLC's price-to-earnings ratio is 15.19x while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 9.26x versus 21.61x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Theravance Biopharma has a net margin of 41.95% compared to Royalty Pharma PLC's net margin of -88.24%. Royalty Pharma PLC's return on equity of 10.92% beat Theravance Biopharma's return on equity of -31.51%.

Royalty Pharma PLC has a consensus price target of $41.90, signalling upside risk potential of 17.73%. On the other hand Theravance Biopharma has an analysts' consensus of $17.20 which suggests that it could grow by 52.89%. Given that Theravance Biopharma has higher upside potential than Royalty Pharma PLC, analysts believe Theravance Biopharma is more attractive than Royalty Pharma PLC.

Royalty Pharma PLC has a beta of 0.503, which suggesting that the stock is 49.658% less volatile than S&P 500. In comparison Theravance Biopharma has a beta of -0.018, suggesting its less volatile than the S&P 500 by 101.836%.

Royalty Pharma PLC has a quarterly dividend of $0.22 per share corresponding to a yield of 2.42%. Theravance Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma PLC pays 43.83% of its earnings as a dividend. Theravance Biopharma pays out -- of its earnings as a dividend. Royalty Pharma PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma PLC quarterly revenues are $568.2M, which are larger than Theravance Biopharma quarterly revenues of $15.4M. Royalty Pharma PLC's net income of $238.3M is higher than Theravance Biopharma's net income of -$13.6M. Notably, Royalty Pharma PLC's price-to-earnings ratio is 15.19x while Theravance Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma PLC is 9.26x versus 8.48x for Theravance Biopharma. Usually stocks with elevated PS ratios are considered overvalued.